Cytori Therapeutics has expanded its Celution system's CE mark approval to include several new indications including cryptoglandular fistula. The Celution system, which pulls stem cells and other regenerative cells out of fat , provides ...
Tags: Cytori Therapeutics, cryptoglandular fistula, celution system
Pluristem Therapeutics, a developer of placenta-based cell therapies, is seeking FDA orphan drug status for its PLacental eXpanded (PLX) cells for the treatment of aplastic anemia. Pluristem earlier received an orphan drug status from the ...
Cytori Therapeutics has treated first US patient in the ATHENA trial using the company's cell therapy based on patient's own adipose-derived stem and regenerative cells (ADRCs). ADRCs are processed using the company's proprietary Celution ...
Life Technologies Corporation's OpTmizer CTS T-Cell Expansion Tissue Culture Medium has received FDA 510(k) clearance as a Class II medical device to transit studies from the research bench to clinical trials. The OpTmizer CTS, as a ...
Tags: FDA, clinical technology, clinical trials
Athersys has received FDA orphan drug designation for its proprietary cell therapy, MultiStem, to treat Hurler's syndrome, also known as mucopolysaccharidosis type I or MPS-I. The orphan drug designation provides substantial potential ...